# OnCo record foresight-clarity (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/foresight-clarity/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "foresight-clarity" ;
  schema:name "Foresight CLARITY"@en ;
  schema:alternateName "CLARITY MRD"@en, "Foresight CLARITY MRD"@en, "PhasED-Seq MRD assay"@en, "Foresight CLARITY" ;
  schema:description "A blood test for leftover lymphoma that looks for several of the tumour's mutations sitting on the same piece of DNA, which lets it see far smaller traces than tests that look for one mutation at a time."@en ;
  schema:url <https://onco.cc/drugs/foresight-clarity/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.foresight-dx.com/>, <https://doi.org/10.18632/oncotarget.28719> ;
  onco:status "emerging" ;
  onco:tag "test", "mrd" ;
  onco:modality "Tumour-informed ctDNA minimal residual disease test (phased variants, PhasED-Seq)" ;
  onco:related <https://onco.cc/drugs/signatera/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:companies <https://onco.cc/companies/foresight-diagnostics/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-klimova-phased-seq-validation-oncotarget-2025/>, <https://onco.cc/key-papers/paper-kurtz-nat-biotechnol/> .